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research subjects with melanoma and non-small cell lung carcinoma (NSCLC) and
peripheral blood leukocytes (PBL) from healthy donors.
Methods: Total RNA from 63melanoma and 19 NSCLC tumor biopsy research sam-
ples (non-FFPE) was extracted for use in long-amplicon TCRB chain sequencing
(mean amplicon of 330bp covering CDR1, 2 and 3) via the Oncomine TCR Beta-LR
Research Assay. To evaluate T cell convergence, we searched for instances where TCRB
chains were identical in amino acid space but had distinct nucleotide sequences owing
to N-addition and exonucleotide chewback within the V-D and D-J junctions of the
CDR3. To provide context, we evaluated evidence for T cell convergence in PBL T cell
repertoires derived from 16 healthy donors.
Results: Sequencing of melanoma biopsy research samples typically yielded within the
range of 2000 to 8000 clones per sample. Convergent T cell receptors were identified in
the great majority of melanoma and NSCLC tumor infiltrating T cell repertoires having
greater than 100 detected clones (92% and 100%, respectively). The frequency of con-
vergent T cell rearrangements was significantly greater in melanoma andNSCLC tumor
biopsies than T cell repertoires derived from healthy PBL research samples.
Conclusions: These data suggest that T cell convergence may be a common feature of
the melanoma and NSCLC infiltrating T cell repertoire. Convergence was more fre-
quently observed within the TME than T cell repertoires derived from healthy PBL,
consistent with elevated antigen-driven T cell selection within the TME. The finding of
elevated T cell convergence in melanoma and NSCLC suggests that convergence may be
a hallmark of immunogenic tumors. For research use only.
Legal entity responsible for the study: Thermo Fisher Scientific.
Funding: Thermo Fisher Scientific.
Disclosure: T. Looney, G. Lowman, L. Miller, E. Linch: Employee: Thermo Fisher
Scientific.
67P PI3K inhibition and modulation of immune and tumor
microenvironment markers by copanlisib in patients with non-
Hodgkin’s lymphoma or advanced solid tumors
A.H. Awada1, F. Morschhauser2, J-P. Machiels3, G. Salles4, S. Rottey5, S. Rule6,
D. Cunningham7, F. Peyrade8, C. Fruchart9, H-T. Arkenau10, I. Genvresse11,
K. Koechert11, G. Cisternas12, C. Granvil13, C. Pena14, L. Liu14
1Department of Medicine, Institute Jules Bordet, Brussels, Belgium, 2Department of
Hematology, CHRU - Hoˆpital Claude Huriez, Lille, France, 3Oncology, Cliniques
Universitaires St. Luc, Brussels, Belgium, 4Department of Hematology, Civil Hospices of
Lyon, University Claude Bernard Lyon-1, Pierre Benite, France, 5Department of Medical
Oncology, Gent University Hospital, Gent, Belgium, 6Department of Haematology,
Plymouth University, Plymouth, UK, 7Medicine, The Institute of Cancer Research/Royal
Marsden NHS Foundation Trust, Sutton, UK, 8Medical Oncology, Centre Anticancer
Antoine Lacassagne, Nice, France, 9Department of Clinical Hematology, Centre
Francois Baclesse, Caen, France, 10SCRI, Sarah Cannon Research Institute, London, UK,
11Pharmaceutical Division, Bayer AG, Berlin, Germany, 12Oncology, Bayer AG, Berlin,
Germany, 13Clinical Pharmacology, Bayer HealthCare Pharmaceuticals Inc, Whippany,
NJ, USA, 14Clinical Science, Bayer HealthCare Pharmaceuticals Inc, Whippany, NJ, USA
Background: Copanlisib, a pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor
with predominant activity against a and d isoforms, shows immune stimulating effects
and anti-tumor activity in combination with immune checkpoint blockers in tumor
models. Here we explore tumor PI3K signaling and the effects of copanlisib on immune
and tumor microenvironment modulation in subjects with NHL and solid tumors (ST)
in a phase I pharmacodynamic study (NCT02155582).
Methods: Patients received 0.4 or 0.8mg/kg (equivalent to a flat dose of 60mg) copan-
lisib on an intermittent schedule (QW, IV, 3 wks on/1 wk off). Tumor biopsies were
performed at baseline and Day 15. Tumor PI3K isoforms, PTEN, and CD3, CD4 and
CD8 tumor infiltrating lymphocytes (TILs) were assessed by IHC. Plasma protein
markers were measured usingmultiplexed immunoassay. Tumor and lymphoma
responses were based on RECIST 1.1 andmodified Cheson 2007 criteria, respectively.
Results:A total of 61 patients were treated: 33 NHL (20 at 0.4mg/kg and 13 at 0.8mg/
kg) and 28 ST (14 at 0.4mg/kg and 14 at 0.8mg/kg). Among patients treated at 0.8mg/
kg, 2 had CR (PTCL and DLBCL) and 5 had PR (MCL, FL, 2 DLBCL, and endometrial
adenocarcinoma); 1 additional PR (DLBCL) occurred at 0.4mg/kg. Tumor PI3K awas
detected in most NHL (18/19) and ST (22/25) samples with comparable intensity. PI3K
dwas predominantly present in NHL (18/19). PI3K ß and cwere present in a subset of
NHL and ST. PTEN loss was more frequent in ST than NHL. CD3, CD4 and CD8 TIL
numbers were higher in NHL than in ST. At 0.8mg/kg copanlisib decreased tumor
pAKT and pS6 in both NHL and ST, and reduced CD4 TILs in NHL (mean -81%,
n¼ 7), with little effect on CD8 TILs in both NHL and ST. In plasma, copanlisib
decreased cytokine/chemokines (e.g. CCL2, CCL5, CCL17), and factors associated with
macrophages (e.g. CD163, CCL4, CCL22) and Treg cells (IL-2Ra). High baseline levels
of CD27 and IL2Ra were associated with tumor reduction in NHL (p< 0.05,
unadjusted).
Conclusions: The high prevalence of the PI3K isoforms – especially a in both NHL and
ST and d in NHL – is consistent with a role for PI3K signaling in immune suppression.
The immune modulation profile for copanlisib supports combination studies with
immunotherapy.
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Legal entity responsible for the study: Bayer AG.
Funding: Bayer AG.
Disclosure: I. Genvresse, K. Koechert, G. Cisternas, C. Granvil, C. Pena, L. Liu:
Employee: Bayer. All other authors have declared no conflicts of interest.
68P Pan-squamous genomic profiling stratified by anatomic tumor site and
viral association
M. Montesion1, C.H. Chung2, E.S. Sokol1, S.A. Khan3, H. Kang4, L.A. Albacker1,
J.M. Johnson5, G.M. Frampton1, V.A. Miller6, J.S. Ross7, S.M. Ali6
1Cancer Genomics Research, Foundation Medicine, Inc., Cambridge, MA, USA,
2Department of Head and Neck-Endocrine Oncology, H. Lee Moffitt Cancer Center and
Research Institute, Tampa, FL, USA, 3Department of Internal Medicine, University of
Texas Southwestern Medical Center, Dallas, TX, USA, 4Department of Oncology, Johns
Hopkins University School of Medicine, Baltimore, MD, USA, 5Department of Medical
Oncology, Thomas Jefferson University, Philadelphia, PA, USA, 6Clinical Development,
Foundation Medicine, Inc., Cambridge, MA, USA, 7Pathology, Foundation Medicine Inc.,
Cambridge, MA, USA
Background: Squamous cell carcinomas (SCC) have diverse anatomic etiologies butmay
share common genomic biomarkers.We profiled 7,871 unique SCCs across nine anatomic
sites to investigate commonality in genomic alterations (GA), tumormutational burden
(TMB), human papillomavirus (HPV) association, andmutational signatures.
Methods: Tissue from over 8,100 unique SCC samples originating from nine anatomic
sites (anogenital (anus, cervix, penis, vagina, vulva), esophagus, head and neck, lung,
and skin) were sequenced by hybrid capture-based comprehensive genomic profiling
to evaluate GA and TMB. About 3% of non-cutaneous SCC samples had UV signatures,
indicative of potential primary site misdiagnoses, and were filtered from the analysis.
Detection of HPV, including high-risk strains 16, 18, 31, 33, and 45, was implemented
through de novo assembly of non-human sequencing reads and BLASTn comparison
against all viral nucleotide sequences in the NCBI database.
Results: The proportion ofHPVþ patients by anatomic site varied, with the highest being
anal (91%) and cervical (83%). Themutational landscape of each cohort was similar,
regardless of anatomic origin, but clustered based onHPV status. The largest differences
in GA frequency as stratified byHPV- vs. HPVþwere TP53 (87% vs. 12%), CDKN2A
(45% vs. 6%), and PIK3CA (22% vs. 33%). Themedian TMB in cases originating from
HPV-associated sites was similar, regardless of HPV status. Highermedian TMBwas
observed in lung and skin cases, which exhibited significant enrichment ofmutational sig-
natures indicative of tobacco- andUV-inducedDNAdamage, respectively.
Conclusions:HPVþ andHPV- SCC populations have distinct genomic profiles and,
for the latter, anatomic site is correlated with TMB distribution, secondary to associ-
ated carcinogen exposure. As such, biomarkers such as TMB and UV signature can pro-
vide unexpected insight into site of originmisdiagnoses andmay correlate with benefit
from immune checkpoint inhibitors.
Table: 68P
Tumor Site % HPVþ Median
TMB (Interquartile
Range)
% TMB
>¼ 10
% TMB
>¼ 20
Anogenital (n¼ 1213) 76 5 (6) 17 5
Head and Neck (n¼ 1843) 36 4 (5) 15 5
Esophageal (n¼ 416) 6 5 (4) 13 2
Lung (n¼ 3977) 5 9 (8) 43 9
Skin (n¼ 422) 8 40 (69) 68 62
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Background: TMB has emerged as a predictive biomarker of response to immune
checkpoint inhibitors. CheckMate 227 demonstrated that patients with non-small cell
lung cancer (NSCLC) with TMB10mutations/megabase derived enhanced benefit
from first-line treatment with nivolumabþ ipilimumab vs chemotherapy (Hellmann
et al. NEJM 2018). Standardized approaches for the measurement and reporting of
TMB are essential for the real-world implementation of TMB. This study aimed to
refine a bioinformatic pipeline for mutation calling and annotation of whole exome
sequencing (WES) data for TMB assessment.
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